Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02263131
Recruitment Status : Completed
First Posted : October 13, 2014
Results First Posted : April 6, 2015
Last Update Posted : July 9, 2020
Sponsor:
Information provided by (Responsible Party):
Il-Yang Pharm. Co., Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) administered as a single intramuscular injection.

Condition or disease Intervention/treatment Phase
Healthy Biological: IL-YANG FLU Vaccine Prefilled Syringe INJ. Biological: VAXIGRIP Prefilled Syringe INJ. Phase 3

Detailed Description:

This was a multi-center, randomized, double-blind, active-controlled study.

Before initiation of any protocol-specific activities, written informed consent was obtained from each patient and their legally acceptable representatives (consent of the legally acceptable representative was required for children younger than 10 years of age, and for the some sites, for children younger than 7 years of age). Subjects who met all of the eligibility criteria after screening assessments as specified in the protocol, were randomized into the test group or the comparator group in a ratio of 5 to 1 according to the pre-generated site-specific randomization table, and received a single dose or two doses of the study vaccine. The investigator performed the efficacy (immunogenicity) and safety assessments throughout the study. Efficacy data were collected at Visit 1 (prior to vaccination) and at the end-of-study visit for efficacy (immunogenicity) assessments, and for safety assessment, subjects and their legally acceptable representatives were instructed to record any treatment-emergent adverse event in Patient Diary cards.

For all randomized subjects, blood sample was obtained prior to vaccination, and the study vaccine 0.5mL or 0.25mL was administered to the deltoid muscle or anterolateral thigh muscle. For children aged from 6 months to <9 years of age who had not been previously exposed to influenza virus or had not previously received influenza vaccine, another dose of the study vaccine was administered 4 to 5 weeks after the first dose. Blood samples were collected 4 to 5 weeks after the last dose of the study drug for the assessment of antibody titer. All subjects were followed for 6 months after the last dose of the study drug for the safety assessments, and Month 6 follow-up visit was the end-of-study visit.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 416 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Randomized, Double Blind, Active-controlled, Phase Ⅲ Study to Evaluate the Immunogenicity and Safety of 'Ilyang Flu Vaccine Pre-filled Syringe Inj.(Influenza Split Vaccine)' in Healthy Children Aged From 6 Months to < 18 Years.
Study Start Date : October 2013
Actual Primary Completion Date : January 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot Vaccines

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: IL-YANG PFS
IL-YANG FLU Vaccine Prefilled Syringe INJ.
 Biological: IL-YANG FLU Vaccine Prefilled Syringe INJ.
IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
Active Comparator: TIV PFS
VAXIGRIP Prefilled Syringe INJ.
 Biological: VAXIGRIP Prefilled Syringe INJ.
VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of Participants With Healthy Children Aged From 6 Months to <18 Years With Seroconversion [ Time Frame: up to Day28(+7) ]
    Seroconversion is defined as follows. (Case 1) A pre-vaccination (Day 0) HI antibody titer < 1:10 and a post-vaccination (Day 28) HI antibody titer ≥ 1: 40. or (Case 2) a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer.

  2. Percentage of Subjects Achieving Seroconversion for HI Antibody After Administration of the Study Vaccine Depending of the Number of Vaccination [ Time Frame: up to Day28(+7) ]
    Seroconversion: a pre-vaccination (Day 0) hemagglutination-inhibition (HI) antibody titer < 1:10 and a post-vaccination (last vaccination + Day 28) HI antibody titer ≥ 1: 40 (Case 1), or a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (last vaccination + Day 28) HI antibody titer (Case 2),

  3. Seroprotection Rate for HI Antibody [ Time Frame: up to Day28(+7) ]
    Percentage of Participants With Healthy Children Aged From 6 Months to <18 Years With Seroprotection

  4. Seroprotection Rate of HI Antibody [ Time Frame: up to Day28(+7) ]
    Percentage of subjects achieving seroprotection for HI antibody after administration of the study vaccine depending of the number of vaccination


Secondary Outcome Measures :
  1. Geometric Mean Titer* (GMT) of HI Antibody [ Time Frame: Day28(+7) ]
    Geometric Mean Titer (GMT), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.

  2. GMR of HI Antibody Titer Before Vaccination and After Vaccination [ Time Frame: Day28(+7) ]
    Geometric Mean Ratio (GMR), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.

  3. Number of Subjects With a Pre-vaccination (Day 0) HI Antibody Titer < 1:40, Minimum Four-fold Rise in Post-vaccination (Day 28) HI Antibody Titer [ Time Frame: Day28(+7) ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men or women aged from 6 months to < 18 years
  • Subjects were born after full term pregnancy (37 weeks)
  • Voluntary written informed consent was obtained from the subject and the subject's legally acceptable representative (consent of legally acceptable representative was required for subjects younger than 10 years of age (and for subjects younger than 7 years of age for the some institutions)).

Exclusion Criteria:

  • Subject with a known allergy to eggs, chicken, neomycin, gentamicin or any components of the study vaccine
  • Subject who had received an influenza vaccine within the last 6 months
  • Subject who has, or has a family history of, an immune system disorder including immune deficiency disease
  • Subject with a history of Guillain-Barre syndrome
  • Subject with Down's syndrome or cytogenetic disorders.
  • Subject with severe chronic disease which in the investigator's opinion would not make the subject a good candidate for the clinical trial
  • Subject with hemophilia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection
  • Subject who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the study vaccine
  • Subject who had previously received another vaccine within 28 days before administration of the study drug, or is scheduled to receive another vaccine during the study period.
  • Subject who had received immunosuppressant or immune modifying drug within the last 3 months prior to administration of the study vaccine
  • Subject who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or is expecting to be treated with immunoglobulin or blood-derived products during the study.
  • Subject who had participated in another experimental study within 30 days prior to administration of the study vaccine
  • Subject with other clinically significant medical or psychological condition who in the investigator's opinion would not be suitable for the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02263131


Sponsors and Collaborators
Il-Yang Pharm. Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Jin-Han Kang, MD.PhD Seoul St. Mary's Hospital, The Catholic University of Korea
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Il-Yang Pharm. Co., Ltd.
ClinicalTrials.gov Identifier: NCT02263131    
Other Study ID Numbers: IY_IFEZ_CH_301
First Posted: October 13, 2014    Key Record Dates
Results First Posted: April 6, 2015
Last Update Posted: July 9, 2020
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Il-Yang Pharm. Co., Ltd.:
Influenza
Influenza vaccine
Split influenza vaccine
Seasonal influenza vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Respiratory Tract Infections
Infections
Orthomyxoviridae Infections
 RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases